Coartem ®: A decade of patient-centric malaria management

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 6, 2012, Pages 645-659

  Hamed, Kamal ^a   Grueninger, Heiner ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

artemether lumefantrine; chemoprevention; Coartem ; dispersible; elimination; resistance; uncomplicated Plasmodium falciparum malaria

Indexed keywords

AMODIAQUINE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; KETOCONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MEFLOQUINE; NEVIRAPINE; PIPERAQUINE; PRIMAQUINE; PYRIMETHAMINE; QUININE; RITONAVIR; SULFADOXINE;

ANOREXIA; ARTHRALGIA; ASTHENIA; BRADYCARDIA; COMBINATION CHEMOTHERAPY; COUGHING; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DISPERSIBLE TABLET; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FOOD; FOOD DRUG INTERACTION; HEADACHE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; MALARIA; MALARIA FALCIPARUM; MATERNAL CARE; MAXIMUM PLASMA CONCENTRATION; MEDICAL DECISION MAKING; MONOTHERAPY; MYALGIA; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PARASITE LOAD; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PREGNANT WOMAN; QT PROLONGATION; REVIEW;

AFRICA SOUTH OF THE SAHARA; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DISEASE MANAGEMENT; DRUG COMBINATIONS; DRUG RESISTANCE; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84863197154     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.51     Document Type: Review

References (124)

1. WHO. World Malaria Report. WHO, Geneva, Switzerland (2011).
2. Otten M, Aregawi M, Were W et al. Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatment. Malar. J. 8, 14 (2009).
3. Bhattarai A, Ali AS, Kachur SP et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 4(11), E309 (2007).
4. WHO. Guidelines for the Treatment of Malaria (2nd Edition). WHO, Geneva, Switzerland (2010).
5. WHO. WHO Model List of Essential Medicines. WHO, Geneva, Switzerland (2010).
6. WHO. WHO Model List of Essential Medicines for Children. WHO, Geneva, Switzerland (2010).
7. Tshefu AK, Gaye O, Kayentao K et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether- lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375(9724), 1457-1467 (2010).
8. Nambozi M, van Geertruyden JP, Hachizovu S et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar. J. 10, 50 (2011).
9. White NJ, van VM, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37(2), 105-125 (1999). (Pubitemid 29431479)
10. Kokwaro G, Mwai L, Nzila A. Artemether/ lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin. Pharmacother. 8(1), 75-94 (2007). (Pubitemid 46070831)
11. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44(3), 697-704 (2000). (Pubitemid 30117964)
12. Ashley EA, Stepniewska K, Lindegardh N et al. Pharmacokinetic study of artemether- lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health 12(2), 201-208 (2007).
13. Lefèvre G, Carpenter P, Souppart C et al. Interaction trial between artemether- lumefantrine (Riamet) and quinine in healthy subjects. J. Clin. Pharmacol. 42(10), 1147-1158 (2002).
14. Djimde AA, Tekete M, Abdulla S et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 55(9), 3994-3999 (2011).
15. Coartem® international package leaflet. Novartis Pharma AG, Basel, Switzerland (2009).
16. Evaluation of a new chemical entity, CGP56695, as an inhibitor of human P450 enzymes. Report DMPK (CH) 1997/073. Drug metabolism pharmacokinetics. Novartis Pharma AG, Basel, Switzerland (1997).
17. Lefèvre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet®). Clin. Drug Invest. 18, 467-480 (1999). (Pubitemid 30047534)
18. Bindschedler M, Lefevre G, Ezzet F, Schaeffer N, Meyer I, Thomsen MS. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur. J. Clin. Pharmacol. 56(5), 375-381 (2000). (Pubitemid 30666063)
19. Lefèvre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen MS. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur. J. Pharm. Sci. 10(2), 141-151 (2000). (Pubitemid 30155936)
20. Lefèvre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether- lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br. J. Clin. Pharmacol. 54(5), 485-492 (2002). (Pubitemid 35356874)
21. van Agtmael MA, Gupta V, van der Wosten TH, Rutten JP, van Boxtel CJ. Grapefruit juice increases the bioavailability of artemether. Eur. J. Clin. Pharmacol. 55(5), 405-410 (1999). (Pubitemid 29344086)
22. German P, Parikh S, Lawrence J et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J. Acquir. Immune Defic. Syndr. 51(4), 424-429 (2009).
23. Kredo T, Mauff K, Van der Walt JS et al. Interaction between artemether- lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob. Agents Chemother. 55(12), 5616-5623 (2011).
24. Hatz C, Soto J, Nothdurft HD et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am. J. Trop. Med. Hyg. 78(2), 241-247 (2008). (Pubitemid 351844558)
25. van Vugt M, Wilairatana P, Gemperli B et al. Efficacy of six doses of artemether- lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 60(6), 936-942 (1999). (Pubitemid 29296218)
26. van Vugt M, Looareesuwan S, Wilairatana P et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(5), 545-548 (2000).
27. Lefèvre G, Looareesuwan S, Treeprasertsuk S et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 64(5-6), 247-256 (2001).
28. Abdulla S, Sagara I, Borrmann S et al. Efficacy and safety of artemether- lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 372(9652), 1819-1827 (2008).
29. Makanga M, Bassat Q, Falade CO et al. Efficacy and safety of artemether- lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am. J. Trop. Med. Hyg. 85(5), 793-804 (2011).
30. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, De Palacios PI. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 99(6), 459-467 (2005). (Pubitemid 40521344)
31. Arinaitwe E, Sandison TG, Wanzira H et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin. Infect. Dis. 49(11), 1629-1637 (2009).
32. Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem). Malar. J. 8(Suppl. 1), S5 (2009).
33. Achan J, Tibenderana JK, Kyabayinze D et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ 339, B2763 (2009).
34. Elamin SB, Awad AI, Eltayeb IB et al. Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Eur. J. Clin. Pharmacol. 66(3), 231-237 (2010).
35. Mens PF, Sawa P, van Amsterdam SM et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar. J. 7, 237 (2008).
36. Sykes A, Hendriksen I, Mtove G et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin. Infect. Dis. 49(8), 1195-1201 (2009).
37. Bassat Q, Mulenga M, Tinto H et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 4(11), E7871 (2009).
38. Bell DJ, Wootton D, Mukaka M et al. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar. J. 8, 204 (2009).
39. Ajayi IO, Browne EN, Bateganya F et al. Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa. Malar. J. 7, 190 (2008).
40. Faucher JF, Aubouy A, Adeothy A et al. Comparison of sulfadoxine- pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J. Infect. Dis. 200(1), 57-65 (2009).
41. Faye B, Offianan AT, Ndiaye JL et al. Efficacy and tolerability of artesunate- amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop. Med. Int. Health 15(5), 608-613 (2010).
42. Faye B, Ndiaye JL, Tine R et al. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am. J. Trop. Med. Hyg. 82(1), 140-144 (2010).
43. Kobbe R, Klein P, Adjei S et al. A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Malar. J. 7, 261 (2008).
44. Ndiaye JL, Randrianarivelojosia M, Sagara I et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ - a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar. J. 8, 125 (2009).
45. Okafor HU, Shu EN, Oguonu T. Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance. J. Trop. Pediatr. 56(6), 398-406 (2010).
46. Sagara I, Diallo A, Kone M et al. A randomized trial of artesunate- mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am. J. Trop. Med. Hyg. 79(5), 655-661 (2008).
47. Sagara I, Rulisa S, Mbacham W et al. Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether- lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. Malar. J. 8, 63 (2009).
48. Toure OA, Penali LK, Yapi JD et al. A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/ lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Cote dIvoire. Malar. J. 8, 148 (2009).
49. Karunajeewa HA, Mueller I, Senn M et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359(24), 2545-2557 (2008).
50. Valecha N, Srivastava P, Mohanty SS et al. Therapeutic efficacy of artemether- lumefantrine in uncomplicated falciparum malaria in India. Malar. J. 8, 107 (2009).
51. Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, Malik EM. Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan. Ann. Trop. Med. Parasitol. 104(4), 319-326 (2010).
52. Ndiaye JL, Faye B, Gueye A et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar. J. 10, 237 (2011).
53. Yavo W, Faye B, Kuete T et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar. J. 10, 198 (2011).
54. Menan H, Faye O, Same-Ekobo A et al. Comparative study of the efficacy and tolerability of dihydroartemisinin- piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. Malar. J. 10, 185 (2011).
55. Dunyo S, Sirugo G, Sesay S et al. Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia. PLoS One 6(6), E17371 (2011).
56. Toure OA, Kouame MG, Didier YJ et al. Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua koute, Cote dIvoire. Trop. Med. Int. Health 16(3), 290-297 (2011).
57. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. 3, CD007483 (2009).
58. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 8(11), E1001119 (2011).
59. Ouedraogo AL, Bousema T, Schneider P et al. Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS One 4(12), E8410 (2009).
60. Borrmann S, Sallas WM, Machevo S et al. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether- lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop. Med. Int. Health 15(4), 434-441 (2010).
61. Premji ZG, Abdulla S, Ogutu B et al. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar. J. 7, 244 (2008).
62. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans. R. Soc. Trop. Med. Hyg. 98(5), 261-267 (2004). (Pubitemid 38950400)
63. Gurkov R, Eshetu T, Miranda IB et al. Ototoxicity of artemether/ lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar. J. 7, 179 (2008).
64. Carrasquilla G, Baron C, Monsell EM et al. Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 86(1), 75-83 (2012).
65. Falade C, Manyando C. Safety profile of Coartem: the evidence base. Malar. J. 8(Suppl. 1), S6 (2009).
66. Adjei GO, Kurtzhals JA, Rodrigues OP et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar. J. 7, 127 (2008).
67. Maiteki-Sebuguzi C, Jagannathan P, Yau VM et al. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar. J. 7, 106 (2008).
68. Coartem® Dispersible international package leaflet. Novartis Pharma AG, Basel, Switzerland (2009).
69. Bassat Q, Gonzalez R, Machevo S et al. Similar efficacy and safety of artemether- lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Malar. J. 10(1), 369 (2011).
70. Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during pregnancy: a pressing question. Malar. J. 6, 15 (2007).
71. Sowunmi A, Oduola AM, Ogundahunsi OA et al. Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sufadoxine-pyrimethamine-resistant falciparum malaria during pregnancy. J. Obstet. Gynaecol. 18(4), 322-327 (1998). (Pubitemid 28310300)
72. Adam I, Elwasila E, Mohammed Ali DA, Elansari E, Elbashir MI. Artemether in the treatment of falciparum malaria during pregnancy in eastern Sudan. Trans. R. Soc. Trop. Med. Hyg. 98(9), 509-513 (2004). (Pubitemid 38987085)
73. Wang TY. Follow-up observation on the therapeutic effects and remote reactions of artemisinin (Qinghaosu) and artemether in treating malaria in pregnant woman. J. Tradit. Chin. Med. 9(1), 28-30 (1989).
74. Manyando C, Mkandawire R, Puma L et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar. J. 9, 249 (2010).
75. Adam I, Elhassan EM, Omer EM, Abdulla MA, Mahgoub HM, Adam GK. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann. Trop. Med. Parasitol. 103(3), 205-210 (2009).
76. McGready R, Stepniewska K, Lindegardh N et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62(12), 1021-1031 (2006). (Pubitemid 44786494)
77. Piola P, Nabasumba C, Turyakira E et al. Efficacy and safety of artemether- lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect. Dis. 10(11), 762-769 (2010).
78. McGready R, Tan SO, Ashley EA et al. A randomised controlled trial of artemether- lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 5(12), E253 (2008).
79. Kaye DK, Nshemerirwe R, Mutyaba TS, Ndeezi G. A randomized clinical trial comparing safety, clinical and parasitological response to artemether- lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. J. Infect. Dev. Ctries. 2(2), 135-139 (2008).
80. Bassat Q. The use of artemether- lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl. Trop. Dis. 5(12), E1325 (2011).
81. Krudsood S, Tangpukdee N, Muangnoicharoen S et al. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J. Parasitol. 45(2), 111-114 (2007).
82. Bassat Q. The use of artemether- lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl. Trop. Dis. 5(12), E1325 (2011).
83. WHO Prequalified Medicines List. WHO, Geneva, Switzerland (2010).
84. Abdulla S, Amuri B, Kabanywanyi AM et al. Early clinical development of artemether- lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects. Malar. J. 9, 253 (2010).
85. Kurth F, Belard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect. Dis. 10(2), 125-132 (2010).
86. Larru B, Molyneux E, ter Kuile FO, Taylor T, Molyneux M, Terlouw DJ. Malaria in infants below six months of age: retrospective surveillance of hospital admission records in Blantyre, Malawi. Malar. J. 8, 310 (2009).
87. Meremikwu M, Alao MJ, Gbadoe AD et al. Efficacy, safety and PK of artemether- lumefantrine dispersible tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infants <5 kg body weight. Am. J. Trop. Med. Hyg. 85 SUPPL. 6 387 2011.
88. Barnes KI, Durrheim DN, Little F et al. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med. 2(11), E330 (2005).
89. Zurovac D, Ndhlovu M, Sipilanyambe N et al. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar. J. 6, 31 (2007).
90. Chizema-Kawesha E, Mukonka VM, Mwanza M et al. Evidence of substantial nationwide reduction of malaria cases and deaths due to scale-up of malaria control activities in Zambia, 2001-2008. World Health Organization, Zambia 19-23 January 2009. Impact Evaluation Mission Report. WHO, Geneva, Switzerland (2009).
91. WHO. Global Malaria Programme, June 2009. Deployment of artemether- lumefantrine with rapid diagnostic tests at community level, Raya Valley, Tigray, Ethiopia. WHO, Geneva, Switzerland (2009).
92. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. WHO, Geneva, Switzerland (2010).
93. Denis MB, Tsuyuoka R, Lim P et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop. Med. Int. Health 11(12), 1800-1807 (2006). (Pubitemid 44813874)
94. Song J, Socheat D, Tan B et al. Randomized trials of artemisinin- piperaquine, dihydroartemisinin-piperaquine phosphate and artemether- lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar. J. 10, 231 (2011).
95. WHO. Update on Artemisinin Resistance - September 2011. WHO, Geneva, Switzerland (2011).
96. WHO. Global Plan for Artemisinin Resistance Containment (GPARC). WHO, Geneva, Switzerland (2011).
97. Dondorp AM, Fairhurst RM, Slutsker L et al. The threat of artemisinin-resistant malaria. N. Engl. J. Med. 365(12), 1073-1075 (2011).
98. Rahman MM, Dondorp AM, Day NP et al. Adherence and efficacy of supervised versus non-supervised treatment with artemether/ lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans. R. Soc.Trop. Med. Hyg. 102(9), 861-867 (2008).
99. Kabanywanyi AM, Lengeler C, Kasim P et al. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Malar. J. 9, 48 (2010).
100. Fogg C, Bajunirwe F, Piola P et al. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am. J. Trop. Med. Hyg. 71(5), 525-530 (2004). (Pubitemid 39601144)
101. Simba DO, Kakoko D, Tomson G et al. Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania. Trans. R. Soc. Trop. Med. Hyg. 106(1), 3-9 (2012).
102. Mace KE, Mwandama D, Jafali J et al. Adherence to treatment with artemether- lumefantrine for uncomplicated malaria in rural Malawi. Clin. Infect. Dis. 53(8), 772-779 (2011).
103. Barrington J, Wereko-Brobby O, Ward P, Mwafongo W, Kungulwe S. SMS for life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology. Malar. J. 9, 298 (2010).
104. Feachem RG, Phillips AA, Hwang J et al. Shrinking the malaria map: progress and prospects. Lancet 376(9752), 1566-1578 (2010).
105. WHO Global Malaria Programme. Update on Artemisinin Resistance - September 2011. WHO, Geneva, Switzerland (2011).
106. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52(5), 1589-1596 (2008). (Pubitemid 351614647)
107. Tarning J, Lindegardh N, Annerberg A et al. Pitfalls in estimating piperaquine elimination. Antimicrob. Agents Chemother. 49(12), 5127-5128 (2005). (Pubitemid 41778931)
108. malERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 8(1), e1000402 (2011).
109. Meister S, Plouffe DM, Kuhen KL et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334(6061), 1372-1377 (2011).
110. Wu T, Nagle A, Kuhen K et al. Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J. Med. Chem. 54(14), 5116-5130 (2011).
111. Mabunda S, Aponte JJ, Tiago A, Alonso P. A country-wide malaria survey in Mozambique. II. Malaria attributable proportion of fever and establishment of malaria case definition in children across different epidemiological settings. Malar. J. 8, 74 (2009).
112. Vafa M, Troye-Blomberg M, Anchang J, Garcia A, Migot-Nabias F. Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants. Malar. J. 7, 17 (2008).
113. Dal-Bianco MP, Koster KB, Kombila UD et al. High prevalence of asymptomatic Plasmodium falciparum infection in Gabonese adults. Am. J. Trop. Med. Hyg. 77(5), 939-942 (2007). (Pubitemid 351837845)
114. Dunyo S, Milligan P, Edwards T, Sutherland C, Targett G, Pinder M. Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clin. Trials 1(4), E20 (2006).
115. Baliraine FN, Afrane YA, Amenya DA et al. High prevalence of asymptomatic Plasmodium falciparum infections in a highland area of western Kenya: a cohort study. J. Infect. Dis. 200(1), 66-74 (2009).
116. Ogutu B, Tiono AB, Makanga M et al. Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? Malar. J. 9, 30 (2010).
117. Doumbia SO, Ndiaye D, Koita OA et al. Improving malaria control in West Africa: interruption of transmission as a paradigm shift. Acta Trop. 121(3), 175-183 (2012).
118. Kern SE, Tiono AB, Makanga M et al. Community screening and treatment of asymptomatic carriers of Plasmodium falciparum with artemether-lumefantrine to reduce malaria disease burden: a modelling and simulation analysis. Malar. J. 10, 210 (2011).
119. von SL, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol. 19(10), 452-460 (2003). (Pubitemid 38366142)
120. von SL, Walraven G, Milligan PJ et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans. R. Soc. Trop. Med. Hyg. 97(2), 217-225 (2003). (Pubitemid 37265637)
121. Zulueta J, Kafuko GW, Mccrae AW, Cullen JR, Pedrsen CK, Wasswa DF. A malaria eradication experiment in the highlands of Kigezi (Uganda). East Afr. Med. J. 41, 102-120 (1964).
122. Molineaux L, Gramiccia G. The Garki project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. WHO, Geneva, Switzerland (1980).
123. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A. Malaria eradication on islands. Lancet 356(9241), 1560-1564 (2000). SMS for Life. www.smsforlife.com
124. A Community Setting Study of Malaria After Systematic Treatment of Asymptomatic Carriers of P. Falciparum With AL/ AL Dispersible. http://clinicaltrials.gov/ct2/show/ NCT01256658